Thelansis

Duchenne Muscular Dystrophy (DMD) Market Outlook Thelansis’s “Duchenne Muscular Dystrophy (DMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Duchenne Muscular Dystrophy (DMD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest ...

  Duchenne Muscular Dystrophy (DMD) Market Outlook Thelansis’s “Duchenne Muscular Dystrophy (DMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Duchenne Muscular Dystrophy (DMD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Duchenne Muscular Dystrophy (DMD) Overview Duchenne muscular dystrophy (DMD) is a rare genetic disorder characterized by the progressive weakening and wasting of muscles, affecting skeletal, smooth, and cardiac muscle tissues. The underlying cause of muscle damage is the absence of the sarcolemmal protein dystrophin due to variations in the DMD gene located on Xp21.2. Symptoms of DMD typically manifest i...

  Capricor Therapeutics, a biotechnology company dedicated to developing transformative cell and exosome-based therapeutics for rare diseases, has announced the initiation of its rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA). This application seeks full approval for their therapy, deramiocel, aimed at treating patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy. This significant step highlights Capricor Therapeutics’ commitment to addressing the unmet medical needs of those affected by DMD cardiomyopathy. Publish Date: 09-10-2024   Source: Capricor Therapeutics Duchenne muscular dystrophy (DMD) is a rare genetic disorder characterized by the progressive weakening and wasting of muscles, affecting skeletal, smooth, and cardiac muscle tissues. The underlying cause of muscle damage is the absence of the sarcolemmal protein dystrophin due to variations in the DMD gene located on Xp2...

  Duchenne muscular dystrophy (DMD) is caused by a lack of dystrophin, a protein that aids in the maintenance of muscle cells. Symptoms usually appear in early childhood, between the ages of 3 and 5. The disease primarily affects boys but can also affect girls in rare cases. Because the gene that can carry a DMD-causing mutation is on the X chromosome, DMD is inherited in an X-linked pattern. Mutations in the DMD gene cause progressive muscle weakness, loss of independent ambulation by early adolescence, and premature death from cardiorespiratory complications. The global DMD prevalence was 7.1 cases per 100,000 males and 2.8 cases per 100,000 in the general population, while the global DMD birth prevalence was 19.8 per 100,000 live male births. Thelansis’s “Duchenne Muscular Dystrophy (DMD) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription shar...